THOR MEDICAL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.02 NOK | 0.00% |
|
+1.80% | -20.93% |
| Jun. 26 | Thor Medical Gets Clearance for Medical Isotope Production in Norway | MT |
| Jun. 06 | Thor Medical Partners With Steenkampskraal for Thorium Feedstock Supply | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 301M 3.21B |
|---|---|---|---|---|---|
| Net income 2022 | -311M -3.32B | Net income 2023 | -26M -277M | EV / Sales 2022 * | - |
| Net cash position 2022 | 98.56M 1.05B | Net cash position 2023 | 41.77M 446M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-8.49
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 38.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on Thor Medical
More press releases
More news
| 1 week | +1.80% | ||
| Current month | -2.86% | ||
| 1 month | +0.79% | ||
| 3 months | +0.39% | ||
| 6 months | -24.44% | ||
| Current year | -20.93% |
1 week
1.00
1.07
1 month
1.001.32
Current year
0.851.53
1 year
0.852.30
3 years
0.852.30
5 years
0.852.30
10 years
0.852.30
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 1.02 | -0.39% | 138,154 |
| 24-07-01 | 1.024 | -2.48% | 147,941 |
| 24-06-28 | 1.05 | +2.74% | 241,844 |
| 24-06-27 | 1.022 | +0.20% | 294,553 |
| 24-06-26 | 1.02 | +1.80% | 759,884 |
Real-time Oslo Bors, July 02, 2024 at 10:45 am EDT
More quotes
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
Calendar
2024-08-29
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -20.93% | 22.52M | |
| +16.44% | 122B | |
| +18.94% | 114B | |
| +19.62% | 25.71B | |
| -25.37% | 19.02B | |
| -20.21% | 15.83B | |
| -20.20% | 15.32B | |
| -47.37% | 14.88B | |
| +59.91% | 14.82B | |
| +4.35% | 14.1B |
- Stock Market
- Equities
- NANOV Stock
